Alternatives to Improve Medical Countermeasure (MCM) Logistics and Administration
Closed Solicitation Posted
- Solicitation number
- CBD254-001
- Agency
-
Joint PEO Chemical and Biological Defense
Acquisition Support Center, Department of Defense
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- More information
Notice details come from DoD SBIR/STTR (DSIP). Updated .
About this opportunity
The Department of the Army Acquisition Support Center's Joint PEO Chemical and Biological Defense seeks Phase I and Phase II SBIR proposals under DoD topic CBD254-001 for technologies that eliminate cold chain requirements for storage and transport of medical countermeasures, with a February 26, 2025 due date that has passed. The Set Aside is Total Small Business, and the notice is not sole-source. Multiple awards are anticipated in both phases. Proposals are submitted through the Defense SBIR/STTR Innovation Portal at dodsbirsttr.mil.
Phase I requires proof-of-concept studies showing advanced development feasibility, integration into DoD manufacturability and sustainment, regulatory experience or strategy, and a commercialization strategy providing long-term DoD access. Phase II requires stabilization of DoD-manufactured medical countermeasures through temperature-variable trials at 25C and -40C for at least six months, ideally a year or more, with efficacy evaluated through in vitro assays, bridging assays, or animal models. The notice is not ITAR-controlled, and its projected CMMC level is N/A.
The attached proposal instructions, a GovTribe AI summary, list Phase I awards up to $209,575.00 for up to six months and Direct to Phase II base amounts up to $698,582.50 for twelve months, with a twelve-month option bringing the total to $1,397,165.00. All awards are subject to funding availability. Per the same file, Phase I technical volumes are limited to 20 pages, and Direct to Phase II submissions require 5 pages of feasibility documentation and a 10-page technical proposal. Phase I prohibits human or animal subjects, while Phase II may include them with appropriate DoD approvals. The program does not participate in Technical and Business Assistance.
The notice cites NAICS 541715 and PSC AC12. Questions go to Ms. Abigail L. Roots at dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil.
Notice text
DoD SBIR topic CBD254-001
Component: CBD
Command: CBD
Phase: SBIR Program Phase I Action; SBIR Program Phase II Action
Technology Areas: Chem Bio Defense
Focus Areas: Biotechnology
Keywords: Cold chain; medical countermeasure; MCM, formulation; stability; temperature-sensitive
ITAR: No
Objective:
Eliminate cold chain requirements for storage and transport of DoD relevant medical countermeasures (MCM).
Description:
The Department of Defense has a need for technologies and approaches to eliminate the cold chain requirements for storage and transportation of medical countermeasures (MCM). This will enable more efficient and expeditionary administration of these critical products through a minimized logistics tail. Existing DoD Chemical and Biological Defense Program developed MCMs will be selected for assessment alongside (1) thermostabilizing technologies, (2) alternative formulations, and or (3) novel routes of administration for long-term MCM efficacy and stability in the absence of cold chain.
Phase I:
Performers will have demonstrated Advanced Development Feasibility through proof-of-concept studies showing technology application and use. Performers should also demonstrate how their technology integrates into DoD manufacturability and sustainment, as well as their regulatory experience and/or strategy. Lastly, performers will be asked to outline a commercialization strategy that involves long-term DoD access. Multiple awards anticipated.
Phase II:
Performers will have demonstrated Prototype Feasibility by demonstrating stabilization of DoD-manufactured MCM(s) through exposure to extended temperature variable trials (i.e., 25°C; - 40°C), for periods extending for at least six months and ideally a year or more.). In addition to stability, efficacy of thermostabilized MCMs will be evaluated using appropriate testing that may include in vitro assays, bridging assays demonstrating equivalency or animal models against current MCM formulations. Multiple awards anticipated.
Direct to Phase II: Eligible Phase II applicants may also apply directly to Phase II awards with support from third-party investors or strategic partners and USG matched funds.
Phase III:
Beyond DoD, effective and efficient cold chain management maximizes utilization of healthcare resources, reduces cold chain products wastage, and improves the quality of health services through increased stability of pharmaceutical supply chain and logistics.
Files
| File | Type | Posted |
|---|---|---|
| CBD254-001.pdf | ||
| CBD_SBIR_254_R4.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity